

91
cont
D2
cont

5. (Three Times Amended) A method of treating a staphylococcal infection associated with a catheter or a prosthetic device, comprising systemically administering to a human suffering from such an infection an effective amount of at least one recombinantly produced lysostaphin analogue; wherein multiple doses per day of the lysostaphin analogue are administered in an amount of 50 mg/kg or less per dose.

C2

32. (Amended) The method of Claim 4, further comprising administering a second antimicrobial agent selected from the group consisting of a rifamycin, a glycopeptide and combinations thereof.

sub D3

41. (Amended) The method of Claim 5, wherein the amount of lysostaphin analogue(s) administered is between 0.5 mg/kg/day and 200 mg/kg/day.

42. (Amended) The method of Claim 32, wherein the amount of lysostaphin analogue(s) administered is between 0.5 mg/kg/day and 200 mg/kg/day.

43. (Amended) The method of Claim 58, wherein the amount of lysostaphin analogue(s) administered is between 0.5 mg/kg/day and 200 mg/kg/day.

44. (Amended) The method of Claim 4, wherein the amount of lysostaphin analogue(s) administered is between 3 mg/kg/day and 50 mg/kg/day.

C3

45. (Amended) The method of Claim 5, wherein the amount of lysostaphin analogue(s) administered is between 3 mg/kg/day and 50 mg/kg/day.

46. (Amended) The method of Claim 32, wherein the amount of lysostaphin analogue(s) administered is between 3 mg/kg/day and 50 mg/kg/day.

47. (Amended) The method of Claim 58, wherein the amount of lysostaphin analogue(s) administered is between 3 mg/kg/day and 50 mg/kg/day.

48. (Amended) The method of Claim 4, wherein the amount of lysostaphin analogue(s) administered is between 3 mg/kg/day and 25 mg/kg/day.

49. (Amended) The method of Claim 5, wherein the amount of lysostaphin analogue(s) administered is between 3 mg/kg/day and 25 mg/kg/day.

50. (Amended) The method of Claim 32, wherein the amount of lysostaphin analogue(s) administered is between 3 mg/kg/day and 25 mg/kg/day.

C3
cond
51. (Amended) The method of Claim 58, wherein the amount of lysostaphin analogue(s) administered is between 3 mg/kg/day and 25 mg/kg/day.

52. (Amended) The method of Claim 4, wherein the amount of lysostaphin analogue(s) administered is no more than 45 mg/kg/day.

53. (Amended) The method of Claim 5, wherein the amount of lysostaphin analogue(s) administered is no more than 45 mg/kg/day. D

54. (Amended) The method of Claim 32, wherein the amount of lysostaphin analogue(s) administered is no more than 45 mg/kg/day.

55. (Amended) The method of Claim 58, wherein the amount of lysostaphin analogue(s) administered is no more than 45 mg/kg/day.

Please add the following new claims:

--56. (New) The method of Claim 32, wherein the at least one lysostaphin analogue is administered simultaneously with the second antimicrobial agent.

C4
57. (New) The method of Claim 4, wherein the at least one organ or tissue is a heart valve.

58. (New) The method of Claim 5, further comprising administering a second antimicrobial agent selected from the group consisting of a rifamycin, a glycopeptide and combinations thereof.